The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Arcus Biosciences Inc | COM | 03969F109 | 35,763 | 3,540,850 | SH | OTR | 1,2,3,6,7,8 | 0 | 3,540,850 | 0 | |
| Constellation Pharmceticls I | COM | 210373106 | 283,117 | 6,009,702 | SH | OTR | 3,4,5,6,7,8,9,10 | 0 | 6,009,702 | 0 | |
| Gritstone Oncology Inc | COM | 39868T105 | 27,833 | 3,102,934 | SH | OTR | 1,2,3 | 0 | 3,102,934 | 0 | |
| NGM Biopharmaceuticals Inc | COM | 62921N105 | 297,077 | 16,066,907 | SH | OTR | 1,2,3,4,5,6,7,8,9,10 | 0 | 16,066,907 | 0 | |
| NGM Biopharmaceuticals Inc | COM | 62921N105 | 6,544 | 353,922 | SH | OTR | 3,8 | 0 | 353,922 | 0 | |
| RAPT Therapeutics Inc | COM | 75382E109 | 185,737 | 6,727,151 | SH | OTR | 1,2,3,6,7,8,9,10 | 0 | 6,727,151 | 0 | |
| RAPT Therapeutics Inc | COM | 75382E109 | 1,381 | 50,000 | SH | OTR | 3 | 0 | 50,000 | 0 | |